BiotechTube

ALN-TTRSC04 + Placebo

Phase 1Completed
0 watching 0 views this week💤 Quiet
30
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Transthyretin-Mediated Amyloidosis

Conditions

Transthyretin-Mediated Amyloidosis

Trial Timeline

Jan 16, 2023 → Sep 30, 2025

NCT ID
NCT05661916

About ALN-TTRSC04 + Placebo

ALN-TTRSC04 + Placebo is a phase 1 stage product being developed by Alnylam Pharmaceuticals for Transthyretin-Mediated Amyloidosis. The current trial status is completed. This product is registered under clinical trial identifier NCT05661916. Target conditions include Transthyretin-Mediated Amyloidosis.

Hype Score Breakdown

Clinical
10
Activity
5
Company
7
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT05661916Phase 1Completed

Competing Products

9 competing products in Transthyretin-Mediated Amyloidosis

See all competitors
ProductCompanyStageHype Score
Eplontersen Solution for InjectionAstraZenecaPhase 1
33
Eplontersen + PlaceboAstraZenecaPhase 3
77
EplontersenAstraZenecaPhase 3
77
PatisiranAlnylam PharmaceuticalsPre-clinical
20
PatisiranAlnylam PharmaceuticalsPre-clinical
20
ALN-TTRSC02 + Sterile Normal Saline (0.9% NaCl)Alnylam PharmaceuticalsPhase 1
30
Nucresiran + VutrisiranAlnylam PharmaceuticalsPhase 3
74
EplontersenIonis PharmaceuticalsPhase 3
74
Inotersen + EplontersenIonis PharmaceuticalsPhase 3
74

Other Products from Alnylam Pharmaceuticals

PatisiranPhase 3
74
PatisiranPhase 3
74
Givosiran + PlaceboPhase 3
74
Nucresiran + Sterile Normal Saline (0.9% NaCl)Phase 3
74
LumasiranPhase 3
74